O-23 - Hot Clinical Trials

Co-Author(s)

• NA

  Nisha Andany, MD, MPH, FRCPC

  Infectious Disease Specialist
  Sunnybrook Health Sciences Centre
  Toronto, Ontario, Canada

  Disclosure: Gilead Sciences (Scientific Research Study Investigator)GlaxoSmithKline (Scientific Research Study Investigator)Janssen (Scientific Research Study Investigator)
• CA

  Charles P. Andrews, MD

  Dr
  Diagnostics Research Group, San Antonio, TX, United States
  San Antonio, Texas

  Disclosure: GSK group of companies (Scientific Research Study Investigator)
• PA

  Pablito Ang, N/A

  Laboratory
  Stanford Health Care
  Stanford, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KB

  Kate Beard, BMBS

  Clinical research fellow
  Clinical and Experiemtnal Sciences
  Universitty of Southampton
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Nathan Brendish, MRCP PhD

  NIHR Clinical Lecturer
  University of Southampton & University Hospitals Southampton NHS Trust
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• CB

  Cynthia Brinson, MD

  Medical Director
  Central Texas Clinical Research
  Austin, Texas

  Disclosure: Gilead (Advisor or Review Panel member, Speaker's Bureau)ViiV Healthcare (Advisor or Review Panel member, Speaker's Bureau)
• GB

  Guillaume Butler-Laporte, MD

  Fellow
  McGill University Health Centre
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JC

  Jerry Cade, MD

  Medical Director
  Wellness Center
  University Medical Center of Southern Nevada
  Las Vegas, Nevada

  Disclosure: Gilead (Consultant, Research Grant or Support, Speaker's Bureau)Janssen Pharmaceutica (Consultant)Merck (Consultant, Research Grant or Support, Speaker's Bureau)ViiV Healthcare (Consultant, Research Grant or Support)
• CC

  Cathleen Chan, MBBS

  Clinical Reserach Fellow
  Infection
  University Hospital Southampton Foundation NHS Trust
  Southmapton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• NC

  Nick Cortes, MBBS

  Consultant in Medical Microbiology
  Hampshire Hospitals Foundation NHS Trust
  Basingstoke, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MD

  Marie-Pierre David, MSc

  Lead statistician
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)
• MD

  Matthew G. Davis, MD

  Medical Director
  Rochester Clinical Research, Rochester, NY, United States
  Rochester, New York

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• SD

  Samuel De L'Etoile-Morel, MD

  Fellow
  Department of Microbiology, division of Infectious Diseases
  McGill University Health Centre
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• ND

  Nathalie De Schrevel, PhD

  Clinical Readout Team Leader
  GSK, Rixensart, Belgium
  Rixensart, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)
• PD

  Philippe De Smedt, MD

  Dr
  University of Antwerp, Antwerp, Belgium
  Antwerp, Antwerpen, Belgium

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JD

  Jerome De Vente, MD

  Principle Investigator
  Long Beach Education and Research Consultants
  Long Beach, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• ND

  Nancy Dezutter, PhD, PharmD, RPh

  Lead Vaccine Development Leader Older Adult Immunization
  GSK, Wavre, Belgium
  Rixensart, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)
• 

  Brandon Essink, MD CPI

  Principal Investigator
  Meridian Clinical Research Omaha, Omaha, NE, United States
  Omaha, NE

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• SE

  Sean Ewings, PhD

  Research Fellow
  University of Southampton
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• LF

  Laurence Fissette, MSc

  Biostatistician
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)
• CF

  Charles Fogarty, MD

  Medical Director
  Spartanburg Medical Research, Spartanburg, SC, United States
  Spartanburg, South Carolina

  Disclosure: GSK group of companies (Grant/Research Support)
• JG

  Javier Ruiz Guiñazú, MD MSc

  Dr
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)
• EK

  Edward Kerwin, MD

  Medical Director
  Crisor, LLC c/o Clinical Research Institute of Southern Oregon, Medford, OR, United States
  Medford, Oregon

  Disclosure: Amphastar (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)AstraZeneca (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Boehringer Ingelheim (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Chiesi (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Cipla (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)GSK group of companies (Employee, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Mylan (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Novartis (Employee, Advisor or Review Panel member, Research Grant or Support, Speaker's Bureau)other around 40 pharmaceutical companies (Other Financial or Material Support, conducted multicenter clinical research trials)Pearl (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Sunovion (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)Theravance (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member, Speaker's Bureau)
• JK

  Juliane Koch, MD

  Safety Physician
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)
• 

  Alexander Lawandi, MD

  Fellow
  Department of Critical Care Medicine, National Institutes of Health Clinical Center
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TL

  Todd Lee, MD, MPH

  Associate Professor of Medicine
  Medicine
  McGill University
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• IL

  Isabel Leroux-Roels, MD PhD

  Professor Dr
  Ghent University Hospital, Ghent, Belgium
  Ghent, Oost-Vlaanderen, Belgium

  Disclosure: GSK group of companies (Scientific Research Study Investigator)
• AM

  Alexandra Madison, MPH CIC FACIP

  Director - Infection Prevention & Control at Stanford Hospital & Clinics
  Stanford Health Care
  Stanford, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AM

  Ahalya Malachira, MD

  Clinical Research Fellow
  University Hospitals Southampton NHS Trust
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• DM

  David Margolis, MD, MPH

  Director of HIV Drug Development
  ViiV Healthcare
  Research Triangle Park, North Carolina

  Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
• CM

  Cynthia McCoig, MD

  Director, R&D
  ViiV Healthcare
  Tres Cantos (Madrid), Madrid, Spain

  Disclosure: ViiV Healthcare (Employee)
• 

  Narcisa Mesaros, MD, MSc

  Dr
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)
• SM

  Samuel Mills, BM BCh

  Clinical Research Fellow
  Infection
  University Hopsital Southampton Foundation NHS Trust
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• CN

  Cheryl Newman, MD

  Professor of Medicine
  Medical College of Georgia
  Augusta University
  Augusta, Georgia

  Disclosure: Gilead (Grant/Research Support)GlaxoSmithKline (Grant/Research Support, Speaker's Bureau)ViiV Healthcare (Research Grant or Support, Speaker's Bureau)
• EN

  Esther Nyimbili, n/a

  Senior Research Nurse
  NIHR Southampton Biomedical Research Centre
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• OO

  Olayemi Osiyemi, M.D

  President
  Triple O Research Institute PA
  West Palm Beach, Florida

  Disclosure: GlaxoSmithKline (Advisor or Review Panel member, Speaker's Bureau)ViiV Healthcare (Advisor or Review Panel member, Speaker's Bureau)
• KP

  Katryn Paquette, M.D.

  Assistant Professor
  Department of Pediatrics, McGill University Health Center, Montreal, Canada
  Montreal, Quebec, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• SP

  Stephen Poole, BMBS

  NIHR (BRC) Clinical Doctoral Research Fellow
  University Hospitals Southampton NHS Trust
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• LP

  Laura Presland, n/a

  Senior Research Nurse
  NIHR Southampton Biomedical Research Centre
  Southampton, England, United Kingdom

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• GR

  Gary Richmond, MD, FACP, FCCP

  Clinical Assistant Professor
  Nova Southeastern University
  Fort Lauderdale, Florida

  Disclosure: Gilead (Scientific Research Study Investigator)TaiMed (Scientific Research Study Investigator)Viv (Scientific Research Study Investigator)
• JR

  Jeremy Roberts, MSc

  Manager, Statistics
  GlaxoSmithKline
  Mississauga, Ontario, Canada

  Disclosure: GSK (Employee)
• TS

  Tammy Schaffner, RN, BSN, CIC

  Manager, Infection Prevention and Control Department
  Infection Prevention and Control
  Stanford Health Care
  Stanford, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• WS

  William Spreen, PharmD

  R&D, Medicine Development Leader
  Global Medical Strategy
  ViiV Healthcare
  Research Triangle Park, North Carolina

  Disclosure: ViiV Healthcare (Employee, Shareholder)
• KS

  Katie Steenackers, MD

  MD
  University of Antwerp, Antwerp, Belgium
  Antwerp, Antwerpen, Belgium

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KS

  Kenneth Sutton, MA

  Clinical Development Manager
  Chief Scientific and Medcial Office
  ViiV Healthcare
  Research Triangle Park, North Carolina

  Disclosure: GlaxoSmithKline (Shareholder)ViiV Healthcare (Employee)
• 

  Jelena Tica, PhD

  Dr
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)
• JT

  Jenny Tran, BLS MLS

  Laboratory Quality Manager
  Stanford Health Care
  Stanford, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• CV

  Corinne Vandermeulen, MD PhD

  Associate Professor
  KU Leuven, Leuven, Belgium
  Leuven, Vlaams-Brabant, Belgium

  Disclosure: GSK group of companies (Other Financial or Material Support, My university only received Grant/Research Support)
• KV

  Kati Vandermeulen, M.SC.

  Senior Director
  Janssen R&D
  Beerse, Antwerpen, Belgium

  Disclosure: Janssen Pharmaceutica (Employee, Shareholder)
• VW

  Viviana Wilches, HBSc, MBiotech

  Clinical Development Manager
  GlaxoSmithKline
  Collegeville, Pennsylvania

  Disclosure: GlaxoSmithKline (Employee, Shareholder)

Presenting Author(s)

• 

  Matthew Cheng, MD

  Assistant Professor
  McGill University Health Center
  Montreal, QC, Canada

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Tristan Clark, BM MRCP DTM&H MD

  Associate Professor
  Clinical and Experimental Sciences
  University of Southampton
  Southampton, England, United Kingdom

  Disclosure: BioFire Diagnostics (Other Financial or Material Support, Equiptment and consumables for the purposes of research)BioMerieux (Other Financial or Material Support, Equipment and consumables for the purposes of research)Qiagen (Other Financial or Material Support, Discounted Equipment and consumables for the purposes of research)

  Slides Slides and Audio
• 

  Narcisa Mesaros, MD, MSc

  Dr
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee)

  Slides Slides and Audio
• 

  Anthony Mills, MD

  Chief Executive Officer/ Principal Investigator
  Men’s Health Foundation/ Mills Clinical Research
  Los Angeles, CA

  Disclosure: Gilead (Grant/Research Support, Advisor or Review Panel member)Janssen Pharmaceutica (Grant/Research Support, Advisor or Review Panel member)Merck (Grant/Research Support, Advisor or Review Panel member)Shionogi (Grant/Research Support)ViiV Healthcare (Grant/Research Support, Advisor or Review Panel member)

  Slides Slides and Audio
• 

  Jelena Tica, PhD

  Dr
  GSK, Wavre, Belgium
  Wavre, Brabant Wallon, Belgium

  Disclosure: GSK group of companies (Employee, Shareholder)

  Slides Slides and Audio
• 

  Lucy Tompkins, MD PhD FIDSA FSHEA

  Professor
  Medicine - Infectious Diseases
  Stanford University School of Medicine
  Stanford, CA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio

Presentations:

• Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study
  Anthony Mills, MD – Men’s Health Foundation/ Mills Clinical Research; Gary J. Richmond, MD, FACP, FCCP – Nova Southeastern University; Cheryl Newman, MD – Augusta University; Olayemi Osiyemi, M.D – Triple O Research Institute PA; Jerry Cade, MD – University Medical Center of Southern Nevada; Cynthia Brinson, MD – Central Texas Clinical Research; Jerome De Vente, MD – Long Beach Education and Research Consultants; Nisha Andany, MD, MPH, FRCPC – Sunnybrook Health Sciences Centre; David Margolis, MD, MPH – ViiV Healthcare; Kenneth Sutton, MA – ViiV Healthcare; Viviana Wilches, HBSc, MBiotech – GlaxoSmithKline; Jeremy Roberts, MSc – GlaxoSmithKline; Cynthia C. McCoig, MD – ViiV Healthcare; Kati Vandermeulen, M.SC. – Janssen R&D; William Spreen, PharmD – ViiV Healthcare
• Adjunctive Daptomycin in the Treatment of staphylococcus Aureus Bacteremia
  Matthew P. Cheng, MD – McGill University Health Center; Alexander Lawandi, MD – Department of Critical Care Medicine, National Institutes of Health Clinical Center; Guillaume Butler-Laporte, MD – McGill University Health Centre; Samuel De L'Etoile-Morel, MD – McGill University Health Centre; Katryn Paquette, M.D. – Department of Pediatrics, McGill University Health Center, Montreal, Canada; Todd C. Lee, MD, MPH – McGill University
• Eliminating Blood Culture Contamination with an Initial-specimen Diversion Device
  Lucy S. Tompkins, MD PhD FIDSA FSHEA – Stanford University School of Medicine; Alexandra Madison, MPH CIC FACIP – Stanford Health Care; Tammy Schaffner, RN, BSN, CIC – Stanford Health Care; Jenny Tran, BLS MLS – Stanford Health Care; Pablito Ang, N/A – Stanford Health Care
• A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Well Tolerated
  Jelena Tica, PhD – GSK, Wavre, Belgium; Javier Ruiz Guiñazú, MD MSc – GSK, Wavre, Belgium; Charles P. Andrews, MD – Diagnostics Research Group, San Antonio, TX, United States; Matthew G. Davis, MD – Rochester Clinical Research, Rochester, NY, United States; Brandon Essink, MD CPI – Meridian Clinical Research Omaha, Omaha, NE, United States; Charles Fogarty, MD – Spartanburg Medical Research, Spartanburg, SC, United States; Edward Kerwin, MD – Crisor, LLC c/o Clinical Research Institute of Southern Oregon, Medford, OR, United States; Isabel Leroux-Roels, MD PhD – Ghent University Hospital, Ghent, Belgium; Katie Steenackers, MD – University of Antwerp, Antwerp, Belgium; Corinne Vandermeulen, MD PhD – KU Leuven, Leuven, Belgium; Marie-Pierre David, MSc – GSK, Wavre, Belgium; Nancy Dezutter, PhD, PharmD, RPh – GSK, Wavre, Belgium; Laurence Fissette, MSc – GSK, Wavre, Belgium; Juliane Koch, MD – GSK, Wavre, Belgium; Narcisa Mesaros, MD, MSc – GSK, Wavre, Belgium
• Impact of a Molecular Point-of-care ‘test and Treat’ Strategy for Influenza in Hospitalised adults: A Multi-centre, Randomised Controlled Trial (FluPOC)
  Tristan William Clark, BM MRCP DTM&H MD – University of Southampton; Kate Beard, BMBS – Universitty of Southampton; Nathan J. Brendish, MRCP PhD – University of Southampton & University Hospitals Southampton NHS Trust; Ahalya Malachira, MD – University Hospitals Southampton NHS Trust; Samuel Mills, BM BCh – University Hopsital Southampton Foundation NHS Trust; Cathleen Chan, MBBS – University Hospital Southampton Foundation NHS Trust; Stephen Poole, BMBS – University Hospitals Southampton NHS Trust; Sean Ewings, PhD – University of Southampton; Nick Cortes, MBBS – Hampshire Hospitals Foundation NHS Trust; Esther Nyimbili, n/a – NIHR Southampton Biomedical Research Centre; Laura Presland, n/a – NIHR Southampton Biomedical Research Centre
• A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic
  Javier Ruiz Guiñazú, MD MSc – GSK, Wavre, Belgium; Jelena Tica, PhD – GSK, Wavre, Belgium; Charles P. Andrews, MD – Diagnostics Research Group, San Antonio, TX, United States; Matthew G. Davis, MD – Rochester Clinical Research, Rochester, NY, United States; Philippe De Smedt, MD – University of Antwerp, Antwerp, Belgium; Brandon Essink, MD CPI – Meridian Clinical Research Omaha, Omaha, NE, United States; Charles Fogarty, MD – Spartanburg Medical Research, Spartanburg, SC, United States; Edward Kerwin, MD – Crisor, LLC c/o Clinical Research Institute of Southern Oregon, Medford, OR, United States; Isabel Leroux-Roels, MD PhD – Ghent University Hospital, Ghent, Belgium; Corinne Vandermeulen, MD PhD – KU Leuven, Leuven, Belgium; Marie-Pierre David, MSc – GSK, Wavre, Belgium; Nancy Dezutter, PhD, PharmD, RPh – GSK, Wavre, Belgium; Nathalie De Schrevel, PhD – GSK, Rixensart, Belgium; Laurence Fissette, MSc – GSK, Wavre, Belgium; Narcisa Mesaros, MD, MSc – GSK, Wavre, Belgium